A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

694

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

October 25, 2016

Study Completion Date

February 23, 2017

Conditions

Chronic Hepatitis CHepatitis C Virus

Interventions

DRUG

ABT-493

Tablet

DRUG

ABT-530

Tablet

DRUG

ribavirin (RBV)

Tablet

DRUG

ABT-493/ABT-530

Tablet; ABT-493 co-formulated ABT-530